Renalytix (RENXF)

OTHER OTC:RENXF

RENXF

Renalytix

RESEARCH TOOLSreports

Renalytix (RENXF) Price & Analysis

8 Followers

RENXF Stock Chart & Stats

$0.08

Market closed

$0.08

Day’s Range― - ―

52-Week Range$0.04 - $0.18

Previous CloseN/A

VolumeN/A

Average Volume (3M)35.00

Market Cap

$11.47M

Enterprise Value$26.40M

Total Cash (Recent Filing)$9.63M

Total Debt (Recent Filing)$8.21M

Price to Earnings (P/E)―

Beta0.21

Next Earnings

Nov 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding437,018,680

10 Day Avg. Volume0

30 Day Avg. Volume35

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)-1.38

Price to Sales (P/S)3.23

P/FCF Ratio-0.54

Enterprise Value/Market Cap2.30

Enterprise Value/Revenue11.13

Enterprise Value/Gross Profit56.42

Enterprise Value/Ebitda-1.14

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue & Margin ImprovementRevenue growth and a material gross margin improvement signal the core KidneyIntelX test is gaining commercial traction and that unit economics can improve as volume rises. Sustained margin expansion supports scalable revenue-to-profit conversion if adoption and reimbursement trends continue.

Proprietary Diagnostic PlatformA combined biomarker-plus-AI diagnostic platform creates a structural competitive advantage through data-driven risk stratification, clinical utility, and barriers to replication. This intellectual-property and clinical integration supports durable differentiation and potential entrenchment in care pathways.

Low Absolute DebtRelatively small nominal debt reduces near-term leverage risk and lowers fixed financing burdens versus larger-carry companies. This modest absolute obligation provides more flexibility for restructuring financing or focusing capital on commercialization and clinical validation initiatives.

Bears Say

Negative EquityNegative equity is a structural capital weakness that limits financial flexibility, can constrain contractual credibility with partners, and typically necessitates ongoing external financing. Over a multi-month horizon this raises dilution and solvency concerns absent sustained cash infusions or profitability improvements.

Persistent Cash BurnSubstantial negative operating and free cash flow indicates the business currently consumes capital faster than it generates it. Continued cash burn forces recurring financing needs, increasing dilution risk and potentially diverting management attention from execution to funding over the coming quarters.

Large Losses; Scale GapExtremely negative net margins show the cost base far exceeds current revenue, implying the company must materially scale test volumes or cut costs to reach break-even. This structural profitability gap creates execution risk and dependency on sustained adoption and reimbursement progress to achieve durable self-sustaining operations.

Renalytix News

Renalytix Grows Revenue and Integration Footprint as It Pursues National Rollout of KidneyintelX.dkd

Renalytix ( ($GB:RENX) ) has issued an announcement. Renalytix reported first-half FY26 revenues of $1.6 million, up from...

17d ago

Renalytix Lifts Revenue as KidneyintelX Expansion and Distribution Talks Gather Pace

Renalytix ( ($GB:RENX) ) has shared an update. Renalytix reported first-half fiscal 2026 revenues of $1.6 million, up...

17d ago

Renalytix CEO Boosts Stake as Kidney Disease Test Rollout Advances

Renalytix ( ($GB:RENX) ) has provided an announcement. Renalytix said Chief Executive James McCullough has increased his stake...

2M ago

Renalytix CFO Increases Stake as KidneyintelX.dkd Deployment Expands

Renalytix ( ($GB:RENX) ) just unveiled an update. Renalytix plc reported that interim Chief Financial Officer Joel Jung...

2M ago

Renalytix CFO Increases Stake as Kidney Disease Test Gains Traction

Renalytix ( ($GB:RENX) ) has provided an announcement. Renalytix announced that interim Chief Financial Officer Joel Jung purchased...

2M ago

Renalytix CEO Increases Stake Amid Expansion of Kidney Disease Test

Renalytix ( ($GB:RENX) ) just unveiled an update. Renalytix plc announced that Chief Executive Officer James McCullough purchased...

2M ago

Renalytix Eyes Revenue Growth as Kidney Diagnostic Expands U.S. Footprint

The latest announcement is out from Renalytix ( ($GB:RENX) ). Renalytix reported unaudited first-half fiscal 2026 revenues of...

2M ago

Renalytix Adds Three U.S. Kidney Care Integrations and Deepens Tempus AI Collaboration

Renalytix ( ($GB:RENX) ) has shared an announcement. Renalytix has expanded the clinical footprint of its kidneyintelX.dkd test...

3M ago

Renalytix Secures Shareholder Support at AGM and Advances Kidney Disease Diagnostics

Renalytix ( ($GB:RENX) ) has provided an announcement. Renalytix announced that all resolutions were passed at its Annual...

4M ago

Renalytix Expands Kidney Disease Test Adoption and Strategic Partnerships

Renalytix ( ($GB:RENX) ) has provided an update. Renalytix has provided an update on its strategic initiatives ahead...

4M ago

RENXF FAQ

What was Renalytix’s price range in the past 12 months?

Renalytix lowest stock price was $0.04 and its highest was $0.18 in the past 12 months.

What is Renalytix’s market cap?

Renalytix’s market cap is $11.47M.

When is Renalytix’s upcoming earnings report date?

Renalytix’s upcoming earnings report date is Nov 03, 2026 which is in 206 days.

How were Renalytix’s earnings last quarter?

Renalytix released its earnings results on Mar 26, 2026. The company reported -$0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.021.

Is Renalytix overvalued?

According to Wall Street analysts Renalytix’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Renalytix pay dividends?

Renalytix does not currently pay dividends.

What is Renalytix’s EPS estimate?

Renalytix’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Renalytix have?

Renalytix has 437,018,680 shares outstanding.

What happened to Renalytix’s price movement after its last earnings report?

Renalytix reported an EPS of -$0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Renalytix?

Currently, no hedge funds are holding shares in RENXF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.